Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients.

Nicolini FE, Dulucq S, Boureau L, Cony-Makhoul P, Charbonnier A, Escoffre-Barbe M, Rigal-Huguet F, Coiteux V, Varet B, Dubruille V, Lenain P, Rousselot P, Rea D, Guerci-Bresler A, Legros L, Liu J, Gardembas M, Ianotto JC, Turlure P, Johnson-Ansah H, Martiniuc J, Jardel H, Joly B, Zunic P, Henni T, Villemagne B, Berger MG, Cayssials E, Guilhot F, Larosa F, Guilhot J, Etienne G, Mahon FX.

Clin Cancer Res. 2019 Nov 15;25(22):6606-6613. doi: 10.1158/1078-0432.CCR-18-3373. Epub 2019 Jul 10.

PMID:
31292142
2.

Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome.

Berger MG, Pereira B, Rousselot P, Cony-Makhoul P, Gardembas M, Legros L, Escoffre-Barbe M, Nicolini FE, Saugues S, Lambert C, Réa D, Guerci-Bresler A, Giraudier S, Guilhot J, Saussele S, Mahon FX; (France Intergroupe des Leucémies Myéloïdes Chroniques).

Br J Haematol. 2019 Nov;187(3):337-346. doi: 10.1111/bjh.16083. Epub 2019 Jul 4.

PMID:
31271217
3.

Contribution of Chronic Myeloid Leukaemia (CML) as a Disease Model to Define and Study Clonal Heterogeneity.

Berger MG, Bourgne C.

Adv Exp Med Biol. 2019;1139:171-185. doi: 10.1007/978-3-030-14366-4_10. Review.

PMID:
31134501
4.

Flow cytometric analysis of neutrophil myeloperoxidase expression in peripheral blood for ruling out myelodysplastic syndromes: a diagnostic accuracy study.

Raskovalova T, Berger MG, Jacob MC, Park S, Campos L, Aanei CM, Kasprzak J, Pereira B, Labarère J, Cesbron JY, Veyrat-Masson R.

Haematologica. 2019 Dec;104(12):2382-2390. doi: 10.3324/haematol.2018.202275. Epub 2019 Apr 19.

5.

Risk-Based Disease Surveillance: The Promise of Early Atrial Fibrillation Identification.

Berger MG, Gutterman D.

Chest. 2019 Mar;155(3):458-459. doi: 10.1016/j.chest.2018.09.005. No abstract available.

6.

Outcome and impact of post-remission strategy after MIDAM regimen in patients with relapsing or refractory acute myeloid leukemia.

Bahashwan S, Moluçon-Chabrot C, Hermet E, Ravinet A, Douge A, Veronese L, Tchirkov A, Lemal R, Berger MG, Veyrat-Masson R, Tournilhac O, Bay JO, Guièze R.

Am J Hematol. 2019 Jan;94(1):E32-E35. doi: 10.1002/ajh.25332. Epub 2018 Nov 25. No abstract available.

PMID:
30370957
7.

Intra-monocyte Pharmacokinetics of Imiglucerase Supports a Possible Personalized Management of Gaucher Disease Type 1.

Berger J, Vigan M, Pereira B, Nguyen TT, Froissart R, Belmatoug N, Dalbiès F, Masseau A, Rose C, Serratrice C, Pers YM, Bertchansky I, Camou F, Bengherbia M, Bourgne C, Caillaud C, Pettazzoni M, Berrahal A, Stirnemann J, Mentré F, Berger MG.

Clin Pharmacokinet. 2019 Apr;58(4):469-482. doi: 10.1007/s40262-018-0708-8.

PMID:
30128966
8.

Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.

Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, Janssen JJWM, Mayer J, Koskenvesa P, Panayiotidis P, Olsson-Strömberg U, Martinez-Lopez J, Rousselot P, Vestergaard H, Ehrencrona H, Kairisto V, Machová Poláková K, Müller MC, Mustjoki S, Berger MG, Fabarius A, Hofmann WK, Hochhaus A, Pfirrmann M, Mahon FX; EURO-SKI investigators.

Lancet Oncol. 2018 Jun;19(6):747-757. doi: 10.1016/S1470-2045(18)30192-X. Epub 2018 May 4.

PMID:
29735299
9.

Evaluation of the coagulometer STA R Max® (Stago) for routine coagulation parameters.

Brulé J, Sinegre T, Pereira B, Berger MG, Serre-Sapin AF, Lebreton A.

Ann Biol Clin (Paris). 2018 Apr 1;76(2):143-149. doi: 10.1684/abc.2018.1333.

PMID:
29623883
10.

DNA methylation profiling reveals a pathological signature that contributes to transcriptional defects of CD34+ CD15- cells in early chronic-phase chronic myeloid leukemia.

Maupetit-Mehouas S, Court F, Bourgne C, Guerci-Bresler A, Cony-Makhoul P, Johnson H, Etienne G, Rousselot P, Guyotat D, Janel A, Hermet E, Saugues S, Berger J, Arnaud P, Berger MG.

Mol Oncol. 2018 Jun;12(6):814-829. doi: 10.1002/1878-0261.12191. Epub 2018 Apr 27.

11.

Nilotinib after imatinib first-line: a real-life longitudinal cohort of patients with chronic myeloid leukaemia in chronic phase.

Cony-Makhoul P, Gardembas M, Coiteux V, Carpentier N, Pommier C, Violet I, Quittet P, Berger MG; TARGET-RMC Investigators.

Br J Haematol. 2018 Feb;180(3):356-364. doi: 10.1111/bjh.15042. Epub 2017 Dec 19.

PMID:
29265184
12.

Bone marrow hematons: An access point to the human hematopoietic niche.

Janel A, Berger J, Bourgne C, Lemal R, Boiret-Dupré N, Dubois-Galopin F, Déchelotte P, Bothorel C, Hermet E, Chabi S, Bay JO, Lambert C, Pereira B, Pflumio F, Haddad R, Berger MG.

Am J Hematol. 2017 Oct;92(10):1020-1031. doi: 10.1002/ajh.24830. Epub 2017 Jul 29.

13.

Management goals for type 1 Gaucher disease: An expert consensus document from the European working group on Gaucher disease.

Biegstraaten M, Cox TM, Belmatoug N, Berger MG, Collin-Histed T, Vom Dahl S, Di Rocco M, Fraga C, Giona F, Giraldo P, Hasanhodzic M, Hughes DA, Iversen PO, Kiewiet AI, Lukina E, Machaczka M, Marinakis T, Mengel E, Pastores GM, Plöckinger U, Rosenbaum H, Serratrice C, Symeonidis A, Szer J, Timmerman J, Tylki-Szymańska A, Weisz Hubshman M, Zafeiriou DI, Zimran A, Hollak CEM.

Blood Cells Mol Dis. 2018 Feb;68:203-208. doi: 10.1016/j.bcmd.2016.10.008. Epub 2016 Oct 24.

14.

A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments.

Stirnemann J, Belmatoug N, Camou F, Serratrice C, Froissart R, Caillaud C, Levade T, Astudillo L, Serratrice J, Brassier A, Rose C, Billette de Villemeur T, Berger MG.

Int J Mol Sci. 2017 Feb 17;18(2). pii: E441. doi: 10.3390/ijms18020441. Review.

15.

Development of myotendinous-like junctions that anchor cardiac valves requires fibromodulin and lumican.

Dupuis LE, Doucette L, Rice AK, Lancaster AE, Berger MG, Chakravarti S, Kern CB.

Dev Dyn. 2016 Oct;245(10):1029-42. doi: 10.1002/dvdy.24435. Epub 2016 Aug 25.

16.

Microbial contamination of transplant solutions during pancreatic islet autotransplants is not associated with clinical infection in a pediatric population.

Berger MG, Majumder K, Hodges JS, Bellin MD, Schwarzenberg SJ, Gupta S, Dunn TB, Beilman GJ, Pruett TL, Freeman ML, Wilhelm JJ, Sutherland DE, Chinnakotla S.

Pancreatology. 2016 Jul-Aug;16(4):555-62. doi: 10.1016/j.pan.2016.03.019. Epub 2016 Apr 6.

PMID:
27134135
17.

Lumican deficiency results in cardiomyocyte hypertrophy with altered collagen assembly.

Dupuis LE, Berger MG, Feldman S, Doucette L, Fowlkes V, Chakravarti S, Thibaudeau S, Alcala NE, Bradshaw AD, Kern CB.

J Mol Cell Cardiol. 2015 Jul;84:70-80. doi: 10.1016/j.yjmcc.2015.04.007. Epub 2015 Apr 15.

18.

Phosphorylation of spleen tyrosine kinase at tyrosine 348 (pSyk³⁴⁸) may be a marker of advanced phase of Chronic Myeloid Leukemia (CML).

Bourgne C, Janel A, Berger J, Rapatel C, Tournilhac O, Hermet E, Guerci A, Lioret F, Briançon A, Bamdad M, Boiret-Dupré N, Berger MG.

Leuk Res. 2015 Mar;39(3):329-34. doi: 10.1016/j.leukres.2014.11.014. Epub 2014 Dec 13.

PMID:
25612940
19.

The chronic lymphocytic leukemia clone disrupts the bone marrow microenvironment.

Janel A, Dubois-Galopin F, Bourgne C, Berger J, Tarte K, Boiret-Dupré N, Boisgard S, Verrelle P, Déchelotte P, Tournilhac O, Berger MG.

Stem Cells Dev. 2014 Dec 15;23(24):2972-82. doi: 10.1089/scd.2014.0229.

PMID:
25055118
20.

The French Gaucher's disease registry: clinical characteristics, complications and treatment of 562 patients.

Stirnemann J, Vigan M, Hamroun D, Heraoui D, Rossi-Semerano L, Berger MG, Rose C, Camou F, de Roux-Serratrice C, Grosbois B, Kaminsky P, Robert A, Caillaud C, Froissart R, Levade T, Masseau A, Mignot C, Sedel F, Dobbelaere D, Vanier MT, Valayanopoulos V, Fain O, Fantin B, de Villemeur TB, Mentré F, Belmatoug N.

Orphanet J Rare Dis. 2012 Oct 9;7:77. doi: 10.1186/1750-1172-7-77.

21.

Measurement of imatinib uptake by flow cytometry.

Bourgne C, Bamdad M, Janel A, Libert F, Gagnieu MC, Rapatel C, Pigeon P, Pereira S, Hermet E, Guerci A, Pereira B, Makhoul PC, Ansah AJ, Cahn JY, Guyotat D, Trouillier S, Berger J, Boiret-Dupré N, Berger MG.

Cytometry A. 2012 Nov;81(11):996-1004. doi: 10.1002/cyto.a.22118. Epub 2012 Aug 28.

22.

The uptake of recombinant glucocerebrosidases by blood monocytes from type 1 Gaucher disease patients is variable.

Berger J, Stirnemann J, Bourgne C, Pereira B, Pigeon P, Heraoui D, Froissart R, Rapatel C, Rose C, Belmatoug N, Berger MG.

Br J Haematol. 2012 Apr;157(2):274-7. doi: 10.1111/j.1365-2141.2011.08989.x. Epub 2012 Jan 9. No abstract available.

PMID:
22224474
23.

Proposal of a score combining red blood cell indices for early differentiation of beta-thalassemia minor from iron deficiency anemia.

Janel A, Roszyk L, Rapatel C, Mareynat G, Berger MG, Serre-Sapin AF.

Hematology. 2011 Mar;16(2):123-7. doi: 10.1179/102453311X12940641877849.

PMID:
21418745
24.

[XE-2100: platelet clumps or polymorphonuclear neutrophil aggregates, that is the question].

Dubois-Galopin F, Lamballais F, Rapatel C, Berger MG.

Ann Biol Clin (Paris). 2010 Jul-Aug;68(4):480-4. doi: 10.1684/abc.2010.0454. French.

25.

Glucocerebrosidase deficiency dramatically impairs human bone marrow haematopoiesis in an in vitro model of Gaucher disease.

Berger J, Lecourt S, Vanneaux V, Rapatel C, Boisgard S, Caillaud C, Boiret-Dupré N, Chomienne C, Marolleau JP, Larghero J, Berger MG.

Br J Haematol. 2010 Jul;150(1):93-101. doi: 10.1111/j.1365-2141.2010.08214.x. Epub 2010 May 9.

PMID:
20507316
26.

Leukoagglutination.

Dubois-Galopin F, Berger MG.

Blood. 2010 Feb 4;115(5):924. No abstract available.

PMID:
20169654
27.

Effects of imiglucerase treatment on traumatic fracture and bone and blood abnormalities in a patient with previously untreated type 1 gaucher disease.

Boiret-Dupré N, Descamps S, Coudoré MA, Rapatel C, Kuentz M, Pereira S, Tournadre J, Berger J, Morell P, Berger MG.

Clin Ther. 2009 Dec;31(12):2900-4. doi: 10.1016/j.clinthera.2009.12.001.

PMID:
20110029
28.

A thrombocytosis occurring in Philadelphia positive CML in molecular response to imatinib can reveal an underlying JAK2(V617F) myeloproliferative neoplasm.

Véronèse L, Tchirkov A, Richard-Pebrel C, Ledoux-Pilon A, Fleury J, Chaleteix C, Goumy C, Gouas L, Berger MG, Vago P, Bay JO, Tournilhac O.

Leuk Res. 2010 Apr;34(4):e94-6. doi: 10.1016/j.leukres.2009.09.025. Epub 2009 Oct 14. No abstract available.

PMID:
19833389
29.

Detection of twelve nucleotides insertion in the BCR-ABL kinase domain in an imatinib-resistant but dasatinib-sensitive patient with bi-phenotypic acute leukemia.

Hayette S, Chabane K, Tchirkov A, Berger MG, Nicolini FE, Tournilhac O.

Haematologica. 2009 Sep;94(9):1324-6. doi: 10.3324/haematol.2009.007864. No abstract available.

30.

Preferential sensitivity of hematopoietic (HPs) and mesenchymal (MPs) progenitors to fludarabine suggests impaired bone marrow niche and HP mobilization.

Berger MG, Berger J, Richard C, Jeanpierre S, Nicolini FE, Tournilhac O, Michallet M, Maguer-Satta V.

Leukemia. 2008 Nov;22(11):2131-4. doi: 10.1038/leu.2008.167. Epub 2008 Jul 3. No abstract available. Erratum in: Leukemia. 2008 Nov;22(11):2135.. Satta, V M [corrected to Maguer-Satta, V].

PMID:
18596744
31.

Mesenchymal content of fresh bone marrow: a proposed quality control method for cell therapy.

Veyrat-Masson R, Boiret-Dupré N, Rapatel C, Descamps S, Guillouard L, Guérin JJ, Pigeon P, Boisgard S, Chassagne J, Berger MG.

Br J Haematol. 2007 Oct;139(2):312-20.

PMID:
17897309
32.

Cell culture medium composition and translational adult bone marrow-derived stem cell research.

Berger MG, Veyrat-Masson R, Rapatel C, Descamps S, Chassagne J, Boiret-Dupre N.

Stem Cells. 2006 Dec;24(12):2888-90. Epub 2006 Aug 31.

33.

Characterization of nonexpanded mesenchymal progenitor cells from normal adult human bone marrow.

Boiret N, Rapatel C, Veyrat-Masson R, Guillouard L, Guérin JJ, Pigeon P, Descamps S, Boisgard S, Berger MG.

Exp Hematol. 2005 Feb;33(2):219-25.

PMID:
15676216
34.

CD34+CDw90(Thy-1)+ subset colocated with mesenchymal progenitors in human normal bone marrow hematon units is enriched in colony-forming unit megakaryocytes and long-term culture-initiating cells.

Boiret N, Rapatel C, Boisgard S, Charrier S, Tchirkov A, Bresson C, Camilleri L, Berger J, Guillouard L, Guérin JJ, Pigeon P, Chassagne J, Berger MG.

Exp Hematol. 2003 Dec;31(12):1275-83.

PMID:
14662335
35.

[Bone marrow mesenchymal stem cells: from characterization to therapeutic use in adults and children].

Berger MG, Chassagne J.

Bull Cancer. 2003 Aug-Sep;90(8-9):771-8. Review. French.

36.

Normal human bone marrow CD34(+)CD133(+) cells contain primitive cells able to produce different categories of colony-forming unit megakaryocytes in vitro.

Charrier S, Boiret N, Fouassier M, Berger J, Rapatel C, Pigeon P, Mareynat G, Bonhomme J, Camilleri L, Berger MG.

Exp Hematol. 2002 Sep;30(9):1051-60.

PMID:
12225797
37.
38.

CFU-Mk content of immunoselected CD34+ peripheral blood progenitor cells, evaluated with an adapted serum-free methylcellulose assay, is predictive of platelet lineage reconstitution in children with solid tumors.

Boiret N, Kanold J, Fouassier M, Bons JM, Halle P, Rapatel C, Berger J, Pireyre P, Blanzat V, Travade P, Bonhomme J, Demeocq F, Berger MG.

J Hematother Stem Cell Res. 2000 Aug;9(4):525-34.

PMID:
10982252
39.
40.

Intracellular acidosis differentially regulates KV channels in coronary and pulmonary vascular muscle.

Berger MG, Vandier C, Bonnet P, Jackson WF, Rusch NJ.

Am J Physiol. 1998 Oct;275(4):H1351-9. doi: 10.1152/ajpheart.1998.275.4.H1351.

PMID:
9746485
41.

Factors influencing the duration of breastfeeding in the Sudbury region.

Bourgoin GL, Lahaie NR, Rheaume BA, Berger MG, Dovigi CV, Picard LM, Sahai VF.

Can J Public Health. 1997 Jul-Aug;88(4):238-41.

PMID:
9336092
42.

Stress measurement in alumina scales on high temperature alloys using X-ray stress evaluation and laser Raman spectroscopy.

Vosberg VR, Fischer W, Berger MG, Clemens D, Quadakkers WJ, Nickel H.

Anal Bioanal Chem. 1996 Jun;355(5-6):745-7.

PMID:
15045361
43.

Rare-earth ion size effect on resistivity, susceptibility, and superconductivity of RBa2Cu3-xZnxO7-y (R= Yb, Er, Y, Dy, Gd, Eu, Sm, and Nd).

Xu Y, Ata-Allah SS, Berger MG, Glück O.

Phys Rev B Condens Matter. 1996 Jun 1;53(22):15245-15253. No abstract available.

PMID:
9983321
44.

Identification of the Ohmic-contact formation mechanism in the Au/Te/Au/GaAs system.

Wuyts K, Langouche G, Watté J, Vanderstraeten H, Silverans RE, Münder H, Berger MG, Lüth H, Van Hove M, Bender H, Van Rossum M.

Phys Rev B Condens Matter. 1992 May 15;45(20):11863-11875. No abstract available.

PMID:
10001202
45.

Implementation of a systematic health maintenance protocol in a private practice.

Hahn DL, Berger MG.

J Fam Pract. 1990 Nov;31(5):492-502; discussion 502-4. Review.

PMID:
2230674
46.

The involvement of glutamine synthetase/glutamate synthase in ammonia assimilation by Aspergillus nidulans.

Kusnan MB, Berger MG, Fock HP.

J Gen Microbiol. 1987 May;133(5):1235-42.

PMID:
2888838
47.

Ammonia Fixation via Glutamine Synthetase and Glutamate Synthase in the CAM Plant Cissus quadrangularis L.

Berger MG, Sprengart ML, Kusnan M, Fock HP.

Plant Physiol. 1986 Jun;81(2):356-60.

48.

Effect of light intensity on ammonia assimilation in maize leaves.

Klaus RE, Berger MG, Fock HP.

Photosynth Res. 1985 Sep;6(3):221-8. doi: 10.1007/BF00049278.

PMID:
24442920
49.

Nitrogen Metabolism in Senescent Flag Leaves of Wheat (Triticum aestivum L.) in the Light.

Berger MG, Woo KC, Wong SC, Fock HP.

Plant Physiol. 1985 Aug;78(4):779-83.

50.

(15)N and inhibitor studies on the photorespiratory nitrogen cycle in maize leaves.

Berger MG, Fock HP.

Photosynth Res. 1983 Jan;4(1):3-7. doi: 10.1007/BF00041796.

PMID:
24458380

Supplemental Content

Loading ...
Support Center